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Introduction
The value of surgical staging in endometrial carcinoma is a subject of debate; as such, there is no uniform approach to lymph node assessment in clinically uterine-confined disease. Staging strategies range from no lymphadenectomy, with the use of preoperative imaging or intraoperative frozen section to guide management, to comprehensive lymphadenectomy. The results of two randomized trials showed no improvement in disease-free or overall survival for patients with early-stage endometrial carcinoma who had undergone systematic pelvic lymphadenectomy [1, 2] . However, in a recent Classification and Regression Tree (CART) analysis, surgical staging, but not the total number of lymph nodes removed, was found to be the most important prognostic factor for overall survival in endometrial cancer [3] . Uterine factors have been shown to be less accurate predictors of recurrence than lymph node status [4, 5] . Taken together, assessing nodal status at the time of initial staging in these patients is imperative.
In the landmark study by Creasman et al, pelvic nodal metastasis was found in 5% of patients with superficial myometrial invasion [6] . When taking into consideration the International Federation of Gynecology and Obstetrics (FIGO) 2009 staging system, Chi et al found that 5.5% of patients with endometrioid histology, all grades and myometrial invasion <50%, had nodal metastasis [7] . Despite the low incidence of nodal disease in these low-risk patients, omitting lymphadenectomy from their surgical management would result in inadequate staging, and consequently either preclude administration of adjuvant therapy when warranted or lead to the overtreatment of certain patients. Comprehensive lymphadenectomy is associated with
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ACCEPTED MANUSCRIPT 5 intraoperative complications, such as increased operating time, nerve and vessel injury, higher blood loss, and postoperative morbidity [8] . The rate of long-term lymphedema directly attributed to lymphadenectomy was recently reported to be 23% [9] . The morbidity associated with comprehensive lymphadenectomy is of particular concern in the low-risk population.
Sentinel lymph node (SLN) mapping is emerging as an acceptable approach for nodal assessment in endometrial carcinoma. This is reflected by the inclusion of an SLN algorithm in the 2014 National Comprehensive Cancer Network (NCCN) guidelines for the management of endometrial cancer [10] . However, when introducing a novel management strategy, we must take great care not to compromise oncologic outcome or inflict harm on our patients. With this in mind, we conducted the following study, in which we sought to assess and compare the clinicopathologic outcomes between two nodal assessment approaches in patients with "lowrisk" endometrial carcinoma as defined by endometrioid histology and limited myoinvasion.
Materials and Methods
Patients with low-risk endometrial cancer at two institutions were identified using the uterine cancer institutional databases at the Mayo Clinic (Mayo) and Memorial Sloan Kettering Cancer Center (MSK). Low risk was defined as endometrioid adenocarcinoma of any grade with myometrial invasion <50%. At one of the institutions, tumor size is not routinely assessed intraor postoperatively. Therefore, tumor size was not included in our risk classification. A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT 6 The Mayo Clinic historical surgical algorithm for the study period was to perform a hysterectomy, bilateral salpingo-oophorectomy (BSO), peritoneal cytology, and bilateral pelvic and para-aortic lymphadenectomy. A gynecologic oncology pathologist performed frozen section of the uterine specimen to determine tumor size and depth of myometrial invasion.
Lymphadenectomy was omitted in patients with disease of endometrioid histology with any grade or tumor size if there was no myometrial invasion, and in patients with disease of endometrioid histology, grade 1 or 2, with <50% myometrial invasion and tumor diameter ≤2 cm (Supplementary Figure 1 ) [11] . At MSK, a previously published SLN algorithm was used per institutional protocol (Supplementary Figure 2 ) [12] . Lymphatic mapping was performed by injecting blue dye or indocyanine green (ICG) into the cervical stroma at superficial and deep levels at the 3-and 9-o'clock positions for a total of 4 mL. Identified SLNs were excised and evaluated by the institutional SLN Pathologic Processing Protocol [13] . Any suspicious nodes were removed regardless of mapping. In cases with no mapping on a hemi-pelvis, a side-specific LND was performed. Para-aortic LND was performed at the surgeon's discretion.
Macrometastasis, micrometastasis, and isolated tumor cells (ITCs) were all considered nodepositive for this analysis. ITCs were defined as those cells measuring ≤0.2 mm, as seen on corresponding hematoxylin and eosin (H&E) sections and not just immunohistochemical (IHC)
staining. Micrometastasis was defined as tumor within a lymph node larger than 0.2 mm but less than 2.0 mm in greatest diameter. Notably, when the tumor measurement was not delineated in the pathology report and the terms "isolated tumor cells" and "micrometastasis"
were not used, a determination was made based on the pathology report, with clarification
from a gynecologic pathologist when needed. For example, "rare scattered tumor cells" were classified as ITCs, whereas "diffuse clusters of cells" were defined as micrometastases. Lymph nodes with a tumor burden ≥2.0 mm were reported as metastatic lymph nodes without further delineation of number or cells or the size of the metastasis. Cytokeratin-positive cells not seen on H&E were considered node-negative. Adjuvant therapy was administered per recommended institutional guidelines.
We compared patient-, treatment-, and disease-specific parameters between cohorts using the chi square or Fisher exact test for categorical variables, the two-sample t test for age and body mass index (BMI), and the Wilcoxon rank-sum test for number of nodes removed and number of positive nodes. Disease-free survival, disease-specific survival, and overall survival were evaluated within the first 3 years after surgery. Survivorship was estimated using the KaplanMeier method and compared between the cohorts using the log-rank test. All calculated P values were two-sided, and P values <0.05 were considered statistically significant.
Results
A total of 1135 cases were identified: 642 in the SLN cohort and 493 in the selective LND cohort. Patient and tumor characteristics are shown in Table 1 Table 1 ).
Adjuvant therapy was administered to 27.1% of patients in the SLN cohort and 10.8% of patients in the LND cohort (P<0.001). Intravaginal brachytherapy (IVRT) alone was administered to 17.6% of patients in the SLN cohort vs 6.1% in the LND cohort (P<0.001). The various combinations of adjuvant therapy are shown in Table 3 .
The median follow-up time was 2.1 years (IQR: The distribution of recurrences for both cohorts is shown in (Figure 1 ). There were 9 deaths within the first 3 years following surgery in the SLN cohort, none of which were due to disease. There were 20
deaths within the first 3 years following surgery in the LND cohort, 5 of which were due to disease. Overall survival was not significantly different between the two cohorts (P=0.07); the 3-year overall survival rates were 97.4% (95% CI, 95.7-99.2%) and 95.4% (95% CI, 93.4-97.4%) in the SLN and LND cohorts, respectively. Disease-specific survival was significantly different between the two cohorts (P=0.03; Figure 2) ; the 3-year disease-specific survival rates were 100% and 98.8% (95% CI, 97.7-99.9), respectively. Multivariate analyses adjusting for other features was not possible due to the small number of disease-related deaths in both cohorts (0 vs 5).
Discussion
There is no uniform practice for surgical staging of uterine-confined endometrial carcinoma.
Patients with <50% myometrial invasion have a low risk of nodal involvement [7] ; therefore, a comprehensive lymphadenectomy may not be necessary in this patient population considering the associated morbidity [8] . Neither the ASTEC trial nor a study by Panici and colleagues
showed a benefit of lymphadenectomy on overall survival [1, 2] ; however, both studies have been extensively criticized. Nearly 50% of the patients in the LND arm of the ASTEC trial had no or ≤9 lymph nodes removed, and 16% of the patients in the non-LND arm in the study by Panici et al had ≥6 lymph nodes removed. Furthermore, both studies allowed bulky nodes to be removed in the non-LND arms, para-aortic LND was left up to the surgeons' discretion, and there was an unequal distribution of high-risk patients and of adjuvant therapy between the study arms, which was not taken into account in their final analysis.
In most institutions, low-risk endometrial cancer is a postoperative diagnosis based on final pathology. The goal of staging women with uterine-confined endometrial cancer is to do as little harm as possible intraoperatively while evaluating nodal status adequately. Such evaluation is important to allow for the tailoring of adjuvant therapy, as uterine factors have been shown to be less accurate predictors of recurrence compared with lymph node status [4, 5] . The Mayo Clinic has published extensively on their approach to intraoperative frozen section to triage patients to no lymphadenectomy or comprehensive lymphadenectomy [14, 15] . In particular, the intraoperative utilization of tumor diameter, in combination with frozen section, can help select patients (27% of the total endometrial cancer population) who can potentially avoid surgical staging [14] . Moreover, even in the absence of frozen section, the intraoperative use of tumor diameter may select those patients with preoperative endometrioid grade 1 or 2 cancer who may not benefit from surgical staging [16] . A French prospective multicenter study has shown that SLN biopsy can accurately diagnose lymph node involvement in patients with low-risk or intermediate-risk endometrial cancer [17] , as have
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other prospective and retrospective studies [18] [19] [20] . It is of great importance to adhere to a surgical SLN algorithm to minimize the false-negative rate when applying the SLN technique [20] . The SENTI-ENDO study's long-term results support the relevance of SLN biopsy on surgical management, as well as on indications for adjuvant therapies [5] .
In our study, we were able to retrospectively compare the historical Mayo LND algorithm to the MSK institutional SLN algorithm [12] . We found that for this low-risk cohort, the SLN algorithm results in significantly more patients having pelvic nodes excised, a lower number of lymph nodes removed per patient, and a higher detection rate in FIGO 2009 stage IIIC1 disease.
Theoretically, SLN mapping should reduce the risk of lower extremity lymphedema, but this has not yet been objectively assessed. When looking at para-aortic nodes, the SLN algorithm results in fewer patients having nodes removed from this anatomic basin, a lower number of nodes excised per patient, and a similar detection rate in stage IIIC2 disease compared with the Mayo LND algorithm. Interestingly, the median number of positive pelvic nodes was the same with both approaches (1; IQR: 1,2), suggesting that the SLN approach is able to identify the positive pelvic lymph node in cases with FIGO 2009 stage IIIC1 disease, and that it is an adequate method for surgical staging. In fact, isolated paraaortic metastases, with negative pelvic lymph nodes, are extremely rare in patients with endometrioid cancer and limited myometrial invasion [21] . For the para-aortic nodes, the median number of positive nodes was 1 versus 3, respectively, suggesting that in those patients with a positive para-aortic lymph node, there may be residual nodal metastasis with the SLN approach. The importance of this latter finding
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The differences between cohorts in age and BMI may have influenced the disease-specific survival in disfavor of the LND cohort. The disproportion of patients without myometrial invasion between the groups may also have played a favorable role for the SLN cohort.
However, the SLN cohort had a significantly higher number of patients with LVI, which is a negative predictive factor. There is institutional variation in the pathologic criteria for the presence of LVI, which limits the interpretation of this finding. Regardless, disease-specific survival was excellent in both cohorts, with a small number of patients dying from their disease.
Adjusting for other factors was not possible because of this low number of deaths. At a minimum, this favorable disease-specific survival outcome in the SLN cohort provides additional reassurance that an SLN mapping algorithm will not lead to unnecessary deaths due to falsenegative staging. This finding would have to be proven in a randomized trial.
The SLN cohort received significantly more adjuvant therapy, mainly IVRT, but also more chemotherapy with or without radiation therapy, compared with the LND cohort. When we excluded the use of IVRT, however, differences in adjuvant treatment were minimal. There may be institutional differences in guiding the administration of adjuvant therapy. Irrespective of this, the higher number of patients with documented LVI in the MSK cohort was responsible for the increased administration of IVRT, and the increased use of chemotherapy with or without radiation therapy corresponds to the higher number of patients with detected stage IIIC
14 disease. It is extremely important to consider the potential added morbidity of any adjuvant therapies, especially in the presence of low-volume metastases in a low-risk cohort of endometrial cancer patients.
Twenty-five of 36 patients with stage IIIC disease in the SLN cohort were staged based on findings of low-volume metastasis. The clinical significance of low-volume metastasis and how it should guide adjuvant therapy remains uncertain. However, in a retrospective case-control surgicopathological study of women with early-stage cervical cancer, low-volume metastases were found to be an important risk factor of tumor recurrence in patients with no apparent lymph node metastasis [22] . In other studies, immunohistochemical expression of cytokeratin in lymph nodes with undetected metastasis predicted occult metastasis and was a risk factor for recurrence in early-stage endometrial cancer [23, 24] . These findings, though limited in numbers, support the removal of low-volume metastasis and adjuvant treatment for these patients. However, in all these reported cases with micrometastases, recurrences occurred when the primary cancers presented with high-risk characteristics and may not specifically apply to our series of low-risk patients [23, 25] . The optimal management of patients with ITCs and micrometastasis in endometrial cancer remains to be determined. However, both follow-up times were >24 months, and the majority of recurrences will occur during this period, and the evaluation of outcomes in this analysis was limited to the first 36 months [25, 26] .
It is important to recognize that the Mayo Clinic algorithm described here is historical, and it has evolved since the study time period in this report. In 2009, the Mayo Clinic modified their protocol, leading to fewer patients requiring a para-aortic lymphadenectomy. In brief, a pelvic and para-aortic lymphadenectomy is performed in patients with either deep (>50%) myoinvasion or Type 2 carcinoma. In cases without either of these features, a pelvic lymphadenectomy is performed if any one of 3 other features are found (cervical invasion, FIGO grade 3 (any myoinvasion), or tumor diameter >2 cm). A para-aortic lymphadenectomy is reserved only in these cases if they are found to have pelvic nodal metastases. SLN mapping has been increasingly incorporated since 2013 [27] .
In conclusion, when comparing these two approaches to surgical staging of low-risk endometrial carcinoma, we found that pelvic lymph nodes were excised in a larger proportion of patients when applying an SLN algorithm versus a selective LND algorithm; however, fewer lymph nodes were removed per patient with the SLN algorithm, the algorithm yielded a higher detection rate in stage IIIC1 disease, and the median number of positive pelvic nodes per patient was the same. For stage IIIC2 disease, both algorithms achieved the same detection rate. The application of an SLN algorithm does not appear to compromise oncologic outcomes within this short follow-up. Our findings strongly support the use of an SLN mapping algorithm, instead of a comprehensive lymphadenectomy, in patients with endometrioid endometrial cancer and myometrial invasion <50%. Of note, patients with grade 1 or 2 cancer and tumor diameter of 2 cm or less may be able to avoid any type of nodal assessment if they can be reliably identified pre-and intraoperatively. The clinical significance of disease detected on ultrastaging and the role of adjuvant therapy in these cases is yet to be determined.
Prospective assessment of the SLN algorithm is needed and currently underway [28] . 
